Instrument Inactif

Cours Transition Therapeutics Inc

Actions

Durée

Période

Style

Transition Therapeutics : Announces Special Shareholder Meeting Voting Results Including Shareholder Approval of the Plan of Arrangement with OPKO Health, Inc.	26/08/16
Transition Therapeutics : Receives Notification From NASDAQ	03/06/16
Transition Therapeutics : Announces Third Quarter Fiscal 2016 Financial Results	11/05/16
Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2016 Financial Results on Wednesday, May 11th, at 4:30 P.M. EST	09/05/16
Transition Therapeutics : Provides Update on Type 2 Diabetes Drug Candidate TT401	18/04/16

Dirigeants	Titre	Age	Depuis
Antonio F. Cruz CEO	Chief Executive Officer	71	06/07/98

Administrateurs	Titre	Age	Depuis
Antonio F. Cruz CEO	Chief Executive Officer	71	06/07/98

Secteur

	Varia. 1 janv.	Capi.
CSL LIMITED	-2,86 %	87,37 Md
SAMSUNG BIOLOGICS CO.,LTD.	+3,95 %	41,01 Md
BIOGEN INC.	-21,94 %	28,08 Md
UCB	+53,11 %	24,72 Md
BIOMARIN PHARMACEUTICAL INC.	-5,41 %	17,47 Md
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44,23 %	11,69 Md
INCYTE CORPORATION	-17,60 %	11,6 Md
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13,96 %	11,56 Md
SWEDISH ORPHAN BIOVITRUM AB	-0,22 %	8,44 Md